Histopathological and Apoptotic Evaluation of Ctvt: Correlating Microscopic Changes With Therapeutic Response

Article

Tumor Necrosis Apoptotic Changes

Histopathological and Apoptotic Evaluation of Ctvt: Correlating Microscopic Changes With Therapeutic Response

Canine Transmissible Venereal Tumor (CTVT) is a unique neoplastic condition characterized by its transmissible nature and distinct biological behavior. While clinical diagnosis is often based on gross appearance, histopathological evaluation plays a crucial role in confirming the diagnosis and assessing treatment response. The tumor exhibits characteristic cellular morphology and undergoes significant structural changes during regression, particularly under chemotherapeutic influence¹.

Histopathological Characteristics of CTVT

Microscopically, CTVT is composed of a heterogeneous population of closely packed tumor cells that are typically round to oval in shape. These cells possess abundant cytoplasm, often with visible vacuolation, and nuclei that vary in size and shape. The nuclear chromatin is coarse and granular, and nucleoli are prominent, usually ranging from one to three in number. The tumor stroma consists of interwoven collagen fibers, and infiltration of lymphocytes, plasma cells, and occasional macrophages is frequently observed. These features support the histological diagnosis and are consistent with previous findings¹.

Changes Observed During Tumor Regression

During treatment, particularly with vincristine scaffold therapy, significant histopathological changes become evident. By the third week, extensive areas of necrosis are observed within the tumor mass. The tumor cells exhibit marked degeneration, with loss of nuclear integrity in many regions. Cells become highly vacuolated, and mitotic activity decreases considerably. In several areas, clusters of tumor cells undergo complete necrosis, forming irregular necrotic zones throughout the tissue.

Apoptosis is a prominent feature of tumor regression. The presence of apoptotic bodies, along with shrunken cells displaying condensed chromatin and fragmented nuclei, indicates active programmed cell death. The increase in apoptotic cells compared to baseline supports the effectiveness of vincristine in inducing tumor regression. These findings align with previously reported mechanisms involving disruption of mitosis and induction of apoptosis^1,2.

Tissue Remodeling and Healing Patterns

As the tumor regresses, histopathological examination reveals progressive healing and tissue remodeling. There is a gradual increase in intercellular collagen deposition, indicating replacement of tumor tissue with connective tissue. Newly formed blood vessels are observed within the submucosa, reflecting active tissue repair. Over time, the tumor site is replaced by mature epithelial tissue with no evidence of residual neoplastic cells¹.

The regressed tumor shows cytoplasmic vacuolation and, in some cases, infiltration of neutrophils along with extensive collagen formation. These changes indicate a transition from active tumor proliferation to tissue repair and restoration. Such findings are consistent with earlier observations¹.

Comparative Histopathology Between Treatment Groups

In animals treated with vincristine scaffolds, the extent of necrosis and apoptosis is significantly higher, leading to rapid tumor regression. In contrast, tumors treated with cisplatin scaffolds show degenerative changes but at a slower rate. Although necrotic areas are present, viable tumor cells persist, and the overall architecture of the tumor remains partially intact for a longer duration¹.

By the fourth week, cisplatin-treated tumors exhibit cells with thickened nuclear material and increased cytoplasmic vacuolation, indicating ongoing but incomplete degeneration. The boundaries of tumor lesions remain indistinct, and the regression process appears less efficient compared to vincristine-treated cases¹.

Diagnostic and Clinical Relevance

Histopathological evaluation not only confirms the diagnosis of CTVT but also provides valuable insights into the effectiveness of therapy. The presence of extensive necrosis, increased apoptosis, and collagen deposition are reliable indicators of successful treatment. Conversely, persistence of viable tumor cells suggests incomplete response and the need for continued or modified therapy¹.

For clinicians, integrating histopathological findings with clinical observations ensures accurate assessment of disease progression and therapeutic outcomes. This approach is particularly important in cases where gross regression may not fully reflect microscopic disease status.

Conclusion

Histopathological and apoptotic evaluation plays a vital role in understanding the progression and regression of CTVT. The marked differences observed between vincristine and cisplatin scaffold therapies highlight the importance of selecting effective treatment modalities. By closely monitoring microscopic changes, clinicians can better evaluate treatment response, ensure complete tumor regression, and improve overall clinical outcomes.

Reference: